BottomFishingCharts Posted - 10 hours ago

#Bitcoin is chewing through $97K atm and momentum is just starting to pivot which bodes well for a 100K #BreakOut.. #LetsGo #Altcoins.. $RARE @SuperRare / $BONK @bonk_inu / $SWFTC @SwftCoin / $MOBILE @helium_mobile @heliumFndn $BTC / $BTC.X

JimiJoJeeter Posted - 23 hours ago

$ABEO With $RARE BLA news on deck b4 EOY, I'm surprised we're not higher; but, it's a good entry point...

CrispDry Posted - 23 hours ago

$MREO $RARE rare is winning between the two

Elvira007 Posted - 2 days ago

$MREO No one and I mean NO ONE wants to see CEO DSK trying to launch Setrusumab for OI in Europe even if its an easy drug to launch with a small sales force. Just give it to $RARE, they already have the salesforce and contacts in place. Why train a new team and screw your partners over. Let them have it, take a 20% royalty (with a big upfront)...Its that fucking easy. Partner out AATD or sell it outright and then go back to looking for new assets to develop and partner again to big pharma....It worked for Ligand. Stock was $10. peaked at $270....They had 20 employees at the time

LDT79 Posted - 2 days ago

@grod86 my guess is they will go solo with $RARE 's milestone payment

CrispDry Posted - 2 days ago

$MREO sold like 80% of my holding and rolled into $RARE

Sergecker Posted - 5 days ago

$BHVN $RARE 😏🚀 MYNZ We know the date of the reverse split (RS) if there will be one, but possibly a Nasdaq extension will be granted. Last time it traded, 50 million and 19 million heavy shorts attacked. Now, it has huge credibility after the TMO partnership and the meeting. The company will decide by November 25th whether or not to do an RS based on Nasdaq's response. Anyway, after the RS, I'm not worried about what happens next. A $210 billion partner TMO signing a deal with a penny stock has never happened before. I will be loading heavy on Monday. This will go to the moon like the DRUG stock recently did. The price target (PT) is $50. The squeeze will be parabolic.

swingingtech Posted - 1 week ago

$RARE https://wallstreetwaves.com/rare-hits-significant-low-crossing-below-key-moving-average/

LDT79 Posted - 1 week ago

@HillbillyWilly @stockythebull she will not release any news whatsoever - Alvelestat will end up like TIGIT - this company's only hope is $RARE with Setrusumab - CEO is completely useless if not detrimental for the stock and company - Rubric is the laziest activist !

BottomFishingCharts Posted - 1 week ago

$RARE .. @SuperRare

BottomFishingCharts Posted - 1 week ago

#AltCoins like $BONK (@bonk_inu), $RARE (@SuperRare) and $JASMY (@JasmyMGT) are starting to #BreakOut and p/u steam... #LetsGo #Bitcoin, $BTC / $BTC.X... #KeepItGoing

RonIsWrong Posted - 1 week ago

$RARE Ultragenyx Presents Positive Update on GTX-102 Angelman Syndrome Program at FAST’s 17th Annual Global Science Summit Phase 1/2 data show improvements across all domains and confirm that Phase 3 Aspire study is amply powered to establish efficacy of GTX-102 Phase 3 program on track to begin enrollment by end-of-year

Stocksrunner Posted - 1 week ago

🔥 Weekend Markets Tea: Just spilled all the hot stock gossip! $PLTR stealing the AI spotlight (again!), $SHW getting that blue-chip glow-up joining the Dow, $RARE crushing it with clinical data, Full tea here https://stocksrunner.com/posts/1355

abubnic Posted - 2 weeks ago

$RARE Q3: 42% increase in income, led by the performance of Crysvita, a treatment for a form of rickets, a bone disease. This drug listed among Ultragenyx’s product line brought in $97.84M for the past three months — about $23M vs the same period last year. https://ir.ultragenyx.com/news-releases/news-release-details/ultragenyx-reports-third-quarter-2024-financial-results-and

360sage Posted - 2 weeks ago

$RARE This is a potential 2-3X opportunity. They are growing, and have a strong pipeline

OutperformGER Posted - 2 weeks ago

$MREO and $RARE for Setrusumab 👇

haitbaslam Posted - 2 weeks ago

$RARE Ultragenyx Pharmaceutical Inc. reported its financial results for the third quarter of 2024 on November 5, after the close of the U.S. markets. Key takeaways include: Financial Performance: Total Revenue: The company reported total revenue of $147 million for the third quarter of 2024, an increase of 36% over the same period in 2023. Crysvita®: Crysvita revenue was $114 million, representing growth of 37% over the third quarter of 2023. The increase was primarily driven by increased international demand. Dojolvi®: Dojolvi revenue was $19 million, up 17% from the prior year. Evkeeza®: Evkeeza revenues reached $8 million, reflecting growing demand in the Company’s territories outside the United States. 2024 Outlook: Ultragenyx raised its full-year 2024 revenue guidance to $530 million to $550 million, compared to its previous estimate of $500 million to $530 million.

DonCorleone77 Posted - 2 weeks ago

$RARE Ultragenyx backs FY24 revenue view $530M-$550M, consensus $536.8M The company said, "Crysvita revenue to be towards the upper end of the range of $375 million to $400 million. This includes all regions where Ultragenyx will recognize revenue: product sales in Latin America and Turkey, royalties in Europe, which have been ongoing, and royalties in North America, which began in April 2023. Dojolvi revenue to be in the range of $75 million to $80 million Net Cash Used in Operations of around $400 million."

DonCorleone77 Posted - 2 weeks ago

$RARE Ultragenyx reports Q3 EPS ($1.40), consensus ($1.45) Reports Q3 revenue $139.49M, consensus $135.79M. "We continue to see substantial year-over-year revenue growth from our commercial portfolio as we expand geographic access to our medicines. This growth could accelerate with up to three near-term BLA submissions and approvals," said Emil Kakkis, chief executive officer and president of Ultragenyx. "Today, we are also sharing an important update from our Phase 3 study in GSDIa with substantially larger reductions in cornstarch intake in crossover patients treated with DTX401. As in our Phase 2 patients, we observed that patients and their physicians were far more comfortable with aggressive titration of cornstarch once they were confirmed to be treated with the gene therapy and had direct access to timely glucose readings."

RonIsWrong Posted - 2 weeks ago

$RARE Ultragenyx Reports Third Quarter 2024 Financial Results and Corporate Update --- Third quarter 2024 total revenue grew 42% versus prior year to $139 million, including Crysvita® revenue of $98 million and Dojolvi® revenue of $21 million Reaffirmed 2024 expected total revenue guidance of $530 million to $550 million Breakthrough Designation granted for setrusumab (UX143) in osteogenesis imperfecta DTX401 Phase 3 follow-up data demonstrated higher and faster 62% mean reduction in cornstarch in crossover patients with glycogen storage disease type Ia (GSDIa)

Estimize Posted - 2 weeks ago

$RARE reports after the close, Estimize Consensus +0.06 EPS and +3.04M Revs compared to WS http://www.estimize.com/rare/fq3-2024?utm_conten

Elvira007 Posted - 2 weeks ago

@Jcody1966 HOLD. Despite CEO being a total fucking LIAR, you have to rely on Ultragenyx and their CEO who is one of the best. He will get Setrusumab across the finish line... Likely, it makes sense for $RARE to acquire MREO. If not, stock still goes higher.....I think worth $15-$20 in a takeout on approval. In terms of their other drugs. No one knows WTF she is doing, especially Alvelestat.

Nyomi__Holloway Posted - 2 weeks ago

$CORT $RARE MYNZ +10.91% PM LFG, unusually high volume activity last week, apx 30% more than average. 👇😘🚀 This stock may see the last time this price per share PT $5+ 🚀 HUGE PRs drop incoming before the Nov 13 meeting, so compliance is coming—no RS needed. Here is why… 1.Frankie Muniz backing Mainz (yes, the Malcolm guy & NASCAR #33 now repping MYNZ). 2.Petra, ex-Obama advisor, hinted at a big U.S. lab partner. Solid source! 3.Six news hits in 3 weeks—momentum. 4.Already solid in the EU, not new but expanding, with insurance covering their tests. 5.Their test has 88% accuracy vs. EXAS (42%) & GH (20%)—big edge! 6.$1.5M private placement in the bag. 7.CEO teased big plans ahead.

ChessGM Posted - 2 weeks ago

$RARE Heads up alert! Only three days until Upcoming Earnings on Tuesday, 11/5/2024 Bullish (8.3) Ultragenyx Pharmaceutical Inc. (RARE) has shown strong momentum recently, particularly with the favorable reception of its investigational therapies. The company received Breakthrough Therapy Designation from the FDA for setrusumab, aimed at treating osteogenesis imperfecta, which positions it favorably within the competitive landscape of rare disease treatments. Additionally, the recent Phase 1/2/3 results for the UX701 gene therapy for Wilson disease indicated superior efficacy compared to standard therapies, suggesting a robust pipeline that could drive future revenue growth. Financially, Ultragenyx aims to leverage its promising clinical data to enhance its market valuation, with the current P/E ratio at 18.5, which is below the industry average of around 20. This suggests that the stock may be undervalued relative to its growth potential. Analysts forecast a 15% year-over-year growth in EPS, driven by anticipated approvals and market entry of its therapies. Revenue estimates for the upcoming quarters reflect optimism, with projections indicating potential growth from $250 million in 2024 to over $400 million by 2026, contingent on successful commercialization of its pipeline products. Regarding upcoming earnings, Ultragenyx is scheduled to report its third-quarter results on November 5, 2024. Analysts are closely watching this event, with consensus estimates suggesting a revenue of approximately $60 million, marking a 25% increase from the prior year. Historical performance during earnings announcements has shown a tendency to meet or exceed expectations, which could bolster investor confidence and drive stock price appreciation. Given the recent positive developments in its drug pipeline and the anticipated financial results, the outlook remains robust, with a potential positive impact on the stock following the earnings call. - Funds were net buyers of $RARE during the previous reporting quarter. - Top 5 funds with large holdings in $RARE: * Alkeon Capital Management LLC $92MM. CGMRank: 91% * Baker Brothers Advisors LP $60MM. CGMRank: 75% * Adage Capital P $46MM. CGMRank: 87% * Avoro Capital Advisors LLC $34MM. CGMRank: 85% * Mpm Bioimpact LLC $16MM. CGMRank: 52% - Last 10 days performance: -7% - Last 30 days performance: -8% - Last 90 days performance: 1% Negative price momentum. Follow ChessGM! Make your move and get timely earnings alerts from ChessGM. Not a financial advice.

360sage Posted - 10/30/24

$RARE Earnings are coming

PDM5 Posted - 1 month ago

$MREO $RARE BofA... "Notably, the company is expecting to take two interim looks at the phase 3 Orbit study evaluating setrusumab in osteogenesis imperfecta (OI) to see if the study can be stopped early to support a bid for approval. The first interim is expected around year-end with the second coming several months after. Our base case continues to assume the study will need to reach at least the second interim so an earlier stop at the first interim would provide upside opportunity. We currently model a launch in 2026 (60% likelihood-of-success) and peak worldwide nominal sales of $1.7bn in 2035. We continue to highlight RARE as one of our top picks of 2024 given a catalyst rich pipeline in high unmet need rare disease indications and reiterate our Buy with $83 PO."

insiderbuyingselling Posted - 1 month ago

$RARE new insider selling: 7465 shares. http://insiderbuyingselling.com/?t=RARE

LDT79 Posted - 1 month ago

$MREO and down we go again while $RARE is up 3% - the hate towards our CEO is real

Westieofwallst Posted - 1 month ago

@LDT79 they have a PR on their website - identical to the $rare one.